Randomized, Double-Blind, Phase II Study of Temozolomide in Combination With Either Veliparib or Placebo in Patients With Relapsed-Sensitive or Refractory Small-Cell Lung Cancer.

Randomized, Double-Blind, Phase II Study of Temozolomide in Combination With Either Veliparib or Placebo in Patients With Relapsed-Sensitive or Refractory Small-Cell Lung Cancer. J Clin Oncol. 2018 08 10; 36(23):2386-2394.

View in: PubMed

subject areas

Adult
Aged
Aged, 80 and over
Antineoplastic Agents, Alkylating
Antineoplastic Combined Chemotherapy Protocols
Benzimidazoles
Biomarkers, Tumor
DNA Methylation
DNA Modification Methylases
DNA Mutational Analysis
DNA Repair Enzymes
Double-Blind Method
Female
Humans
Immunohistochemistry
Lung Neoplasms
Male
Middle Aged
Neoplastic Cells, Circulating
Nuclear Proteins
Placebos
Poly (ADP-Ribose) Polymerase-1
Promoter Regions, Genetic
Small Cell Lung Carcinoma
Tumor Suppressor Proteins

authors with profiles

LAUREN AVERETT BYERS
IGNACIO IVAN WISTUBA
JUNYA FUJIMOTO
ERIK PHILIP SULMAN
JOHN VICTOR HEYMACH
PATRICIA DE GROOT